Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 4/20 | 0.58 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.58 |
| ▸ | HINT1 | P49773 | 4/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | NT5E | P21589 | 1/20 | 0.53 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.51 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27659 | 1.00 | ADORA2A (0.58) | ADORA2AADORA2BHINT1HPGDNT5E | |
| SCHEMBL26198 | 0.97 | ADORA2A (0.58) | ADORA2AADORA2BHINT1HPGDNT5E | |
| SCHEMBL26197 | 0.97 | ADORA2A (0.58) | ADORA2AADORA2BHINT1HPGDNT5E | |
| SCHEMBL5963095 | 0.96 | ADORA2A (0.59) | ADORA2AADORA2BHINT1HPGDNT5E | |
| SCHEMBL2345484 | 0.96 | ADORA2A (0.59) | ADORA2AADORA2BHINT1HPGDNT5E | |
| SCHEMBL24968582 | 0.96 | ADORA2A (0.59) | ADORA2AADORA2BHINT1HPGDNT5E | |
| SCHEMBL31107536 | 0.96 | ADORA2A (0.59) | ADORA2AADORA2BHINT1HPGDNT5E | |
| SCHEMBL2345479 | 0.96 | ADORA2A (0.59) | ADORA2AADORA2BHINT1HPGDNT5E | |
| SCHEMBL5963089 | 0.96 | ADORA2A (0.59) | ADORA2AADORA2BHINT1HPGDNT5E | |
| SCHEMBL27351 | 0.94 | HINT1 (0.59) | ADORA2AADORA2BHINT1HPGDNT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115976028-B | Glycogen disease type Ia therapeutic agent | 第一三共株式会社 | 2025-03-25 | — | — | CN | disclosed |
| CN-114080238-B | Nucleic acid medicine for inhibiting mRNA production of myostatin gene | 神户天然物化学株式会社 | 2025-02-07 | — | — | CN | disclosed |
| CN-119326905-A | GalNAc-oligonucleotide conjugate for delivery to liver and preparation method thereof | 第一三共株式会社 | 2025-01-21 | — | — | CN | disclosed |
| CN-118891366-A | SiRNA inhibiting expression of transferrin receptor 2 | 第一三共株式会社 | 2024-11-01 | — | — | CN | disclosed |
| CN-118871585-A | Chemically-modified oligonucleotides with RNAi activity | 第一三共株式会社 | 2024-10-29 | — | — | CN | disclosed |
| CN-114616332-B | GalNAc-oligonucleotide conjugate for delivery to liver and preparation method thereof | 第一三共株式会社 | 2024-09-20 | — | — | CN | disclosed |
| CN-116981772-A | Nucleic acid pharmaceuticals expressing splice variants of myostatin | 神户天然物化学株式会社 | 2023-10-31 | — | — | CN | disclosed |
| CN-115976028-A | Remedies for glycogen disease type Ia | 第一三共株式会社 | 2023-04-18 | — | — | CN | disclosed |
| CN-115916976-A | Antisense nucleic acid for inducing exon skipping of angiotensin converting enzyme 2 gene | 神户天然物化学株式会社 | 2023-04-04 | — | — | CN | disclosed |
| CN-114616332-A | GalNAc-oligonucleotide conjugates for delivery to liver and methods of making the same | 第一三共株式会社 | 2022-06-10 | — | — | CN | disclosed |
| EP-2530153-A1 | ENA nucleic acid drugs modifying splicing in mRNA precursor | Matsuo, Masafumi (JP) | 2012-12-05 | — | — | EP | disclosed |
| EP-2392660-A2 | ENA Nucleic Acid Drugs Modifying Splicing in mRNA Precursor | Matsuo, Masafumi (JP) | 2011-12-07 | — | — | EP | disclosed |
| EP-2386636-A2 | ENA nucleic acid drugs modifying splicing in mRNA precursor | Matsuo, Masafumi (JP) | 2011-11-16 | — | — | EP | disclosed |
| US-20110254041-A1 | SEMICONDUCTOR LIGHT EMITTING DEVICE AND METHOD OF FABRICATING THE SAME | SUZHOU LEKIN SEMICONDUCTOR CO., LTD. (CN) | 2011-10-20 | — | — | US | disclosed |
| EP-2374885-A2 | ENA nucleic acid drugs modifying splicing in mRNA precursor | Matsuo, Masafumi (JP) | 2011-10-12 | — | — | EP | disclosed |
| US-7902160-B2 | ENA nucleic acid drugs modifying splicing in mRNA precursor | Matsuo, Masafumi (JP) | 2011-03-08 | — | — | US | disclosed |
| US-20110046360-A1 | ENA NUCLEIC ACID DRUGS MODIFYING SPLICING IN mRNA PRECURSOR | Matsuo, Masafumi (JP) | 2011-02-24 | — | — | US | disclosed |
| EP-2135948-A2 | ENA nucleic acid drugs modifying splicing in mRNA precursor | Matsuo, Masafumi (JP) | 2009-12-23 | — | — | EP | disclosed |
| US-20070082861-A1 | Ena nucleic acid drugs modifying splicing in mrna precursor | MASAFUMI MATSUO (JP) | 2007-04-12 | — | — | US | disclosed |
| EP-1568769-A1 | ENA NUCLEIC ACID DRUGS MODIFYING SPLICING IN mRNA PRECURSOR | Matsuo, Masafumi (JP) | 2005-08-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046360-A1 | ENA NUCLEIC ACID DRUGS MODIFYING SPLICING IN mRNA PRECURSOR | SNRPA, RBM17, SNRPA1 | ADORA2A 577/4885ADORA2B 310/4885HINT1 2656/4885 |
| US-20070082861-A1 | Ena nucleic acid drugs modifying splicing in mrna precursor | SNRPA, RBM17, SNRPA1 | ADORA2A 577/4885ADORA2B 310/4885HINT1 2656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.